Greg Pyszczymuka's Net Worth
$462 Thousand
Who is Greg Pyszczymuka?
Greg Pyszczymuka does not have any significant net worth to report based on the numbers we have. This is based on reported shares in AYTU BIOPHARMA, INC.
SEC CIK
Greg Pyszczymuka's CIK is 0001952920
Past Insider Trading and Trends
2023 was Greg Pyszczymuka's most active year for acquiring shares with 6 total transactions. Greg Pyszczymuka's most active month to acquire stocks was the month of May. 2023 was Greg Pyszczymuka's most active year for disposing of shares, totalling 4 transactions. Greg Pyszczymuka's most active month to dispose stocks was the month of May. 2022 saw Greg Pyszczymuka paying a total of $24,480.00 for 100,000 shares, this is the most they've acquired in one year. In 2023 Greg Pyszczymuka cashed out on 1,458 shares for a total of $0.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
AYTU BIOPHARMA, INC (AYTU) Snapshot price: $2.48
Chief Commercial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Nov 6
| |||
Form 4
| +0.91% | 208 |
—
|
—
| 22.98K |
Jun 30
| |||
Form 4
| +0.92% | 208 |
—
|
—
| 22.77K |
Mar 31
| |||
Form 4
| +0.94% | 209 |
—
|
—
| 22.56K |
Dec 31
| |||
Form 4
| +0.94% | 208 |
—
|
—
| 22.35K |
Sep 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 11
| |||
Form 4
| +0.95% | 208 |
—
|
—
| 22.14K |
Jun 30
| |||
Form 4
| +120.79% | 12K |
$1.87 | $22,428.00 | 21.93K |
Jun 16
| |||
Form 4
| +9.15% | 833 |
—
|
—
| 9.94K |
Apr 25
| |||
Form 4
| +121.87% | 100K |
$0.24 | $24,480.00 | 182.06K |
Dec 19
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||